The Promise of Tumor Mutational Burden for Cancer Immunotherapy – Genetic Engineering & Biotechnology News
|
The Promise of Tumor Mutational Burden for Cancer Immunotherapy
Genetic Engineering & Biotechnology News One way to do this is with biomarkers and, for cancer immunotherapy, PD-L1 protein expression is one of the most thoroughly studied. But even from the beginning, it was clear that developing biomarkers for checkpoint inhibitor immunotherapies would be … |
